On Aug. 8, Recursion Pharmaceuticals announced its intention to merge with Exscientia in an all-stock deal. Recursion Pharmaceuticals and Exscientia are both pharma-tech companies that aim to improve ...
Exclusive content, detailed data sets, and best-in-class trade insights to rewrite your portfolio for tomorrow. Nasdaq Listings Host Kristina Ayanian delves into companies' notable accomplishments, ...
In recent developments, Recursion Pharmaceuticals unveiled advances in its AI platform for drug discovery, forming collaborations with major pharmaceutical groups including Sanofi, Roche/Genentech, ...
Recursion Pharmaceuticals Stock Could Be a 10-Bagger, but Only if It Comes Through on This Big Claim
The CEO has set a high bar for the business, and if it hits it, the stock could easily 10x in value. Investing in growth stocks can lead to significant returns for investors in the long run. But ...
Recursion Pharmaceuticals leverages AI and machine learning to revolutionize drug discovery, reducing costs and accelerating development, positioning itself as a leader in tech-driven biopharma. The ...
Recursion Pharmaceuticals' stock has plummeted 57% since February, with significant failures in its lead drug REC-994 and other clinical candidates, raising concerns about its AI-driven drug discovery ...
Shares of Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) are trading higher after the company, in collaboration with MIT, announced the release of Boltz-2, a new open-source AI model designed to predict ...
Recursion has stumbled through an early test of its tech-enabled approach to drug discovery, reporting a hit on its phase 2 primary endpoint of safety and tolerability but failing to wow on the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback